David Simon Ziegler

This study identifies UNSW-SC-22 as a novel MYC/MYCN-targeting molecule that crosses the blood-brain barrier and shows potent preclinical efficacy in medulloblastoma.

This study shows that combining FACT and BET inhibition disrupts oncogenic transcription and extends survival in Diffuse Midline Glioma models.

This study uses single-cell RNA-sequencing of cerebrospinal fluid to identify circulating tumour cells in children with brain cancer, revealing their dynamics and potential as biomarkers.

This paper shows RNA-seq can detect most mutations found by WGS in pediatric tumors and provides additional insights into their pathogenicity.